Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 29;13(4):940-946.
doi: 10.21037/tlcr-24-98. Epub 2024 Apr 25.

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations

Jan Trøst Jørgensen  1 , Edyta M Urbanska  2 , Jens Mollerup  3
Affiliations
Editorial

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations

Jan Trøst Jørgensen et al. Transl Lung Cancer Res. .
No abstract available

Keywords: MET exon 14-skipping mutations (METex14); Non-small-cell lung cancer (NSCLC); capmatinib; companion diagnostics; tepotinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-98/coif). J.T.J. has received consulting fees from Agilent Technologies, Alligator Biosciences, Argenx, Biovica, and Visiopharm; speaker honoraria from AstraZeneca and Leo Pharma; and royalties from Elsevier. E.M.U. reports research funding from Merck and AstraZeneca; honoraria for lectures from Amgen, AstraZeneca, Janssen, and Novartis; support from AstraZeneca and Roche for attending meeting; and is involved in the Advisory Board of Pfizer, Roche, Takeda, and AstraZeneca. J.M. is employed by and holds shares in Agilent Technologies. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Recondo G, Che J, Jänne PA, et al. Targeting MET Dysregulation in Cancer. Cancer Discov 2020;10:922-34. 10.1158/2159-8290.CD-19-1446 - DOI - PMC - PubMed
    1. Mazieres J, Vioix H, Pfeiffer BM, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer 2023;24:483-97. 10.1016/j.cllc.2023.06.008 - DOI - PubMed
    1. Fujino T, Suda K, Sakai K, et al. Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas. Clin Lung Cancer 2022;23:e185-95. 10.1016/j.cllc.2021.09.005 - DOI - PubMed
    1. Abella JV, Peschard P, Naujokas MA, et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 2005;25:9632-45. 10.1128/MCB.25.21.9632-9645.2005 - DOI - PMC - PubMed
    1. Kim SY, Yin J, Bohlman S, et al. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clin Res Rep 2022;3:100381. 10.1016/j.jtocrr.2022.100381 - DOI - PMC - PubMed